鞘氨醇激酶1抑制剂的研究进展

杨倩; 汪小涧

doi:10.11665/j.issn.1000-5048.20210615

鞘氨醇激酶1抑制剂的研究进展

杨倩¹,
汪小涧²

1.
国家知识产权局专利局专利审查协作北京中心，北京 100160
2.
中国医学科学院、北京协和医学院药物研究所，天然药物活性物质与功能国家重点实验室，北京 100050

计量
- 文章访问数: 265
- HTML全文浏览量: 13
- PDF下载量: 825
出版历程
- 收稿日期: 2021-06-02
- 修回日期: 2021-11-04
- 刊出日期: 2021-12-24

Research progress of sphingosine kinase 1 inhibitors

YANG Qian¹,
WANG Xiaojian²

1.
Patent Examination Cooperation (Beijing) Center of the Patent Office, China National Intellectual Property Administration, Beijing 100160
2.
State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100050, China

摘要

摘要: 鞘氨醇激酶1（SphK1）是调控细胞膜脂质微环境的重要蛋白，在神经酰胺，鞘氨醇和鞘氨醇-1-磷酸的动态平衡中发挥重要作用。SphK1的过度表达与肿瘤的发生，发展和迁移过程以及产生耐药性有着密切的联系。SphK1抑制剂可以诱导多种肿瘤细胞凋亡，并且可以逆转肿瘤耐药性，具有良好的药物开发前景。本文综述了SphK1的结构生物学以及SphK1抑制剂的结构类型和构效关系研究进展。
- 鞘氨醇激酶-1 /
- 抑制剂 /
- 抗肿瘤 /
- 结构类型 /
- 构效关系 /
- 进展
Abstract: Sphingosine kinase 1 (SphK1) is an important protein that regulates the lipid microenvironment of cell membranes, and plays an important role in the dynamic equilibrium of ceramide, sphingosine and sphingosine-1-phosphate.The overexpression of SphK1 is closely related to the occurrence, development and migration of tumors as well as the generation of drug resistance.SphK1 inhibitors can induce apoptosis of various tumor cells and reverse drug resistance, which has a good prospect for drug development.In this article, the structural biology of SphK1, the structural types and structure-activity relationships of SphK1 inhibitors are reviewed.
- sphingosine kinase 1 (SphK1) /
- inhibitors /
- anti-tumor /
- structural types /
- SAR /
- advances

HTML全文

参考文献(47)

[1]	. Pharmacol Rev，2008，60（2）：181-195.
[2]	Milstien S，Spiegel S. Targeting sphingosine-1-phosphate：a novel avenue for cancer therapeutics［J］. Cancer Cell，2006，9（3）：148-150.
[3]	Pitson SM. Regulation of sphingosine kinase and sphingolipid signaling［J］. Trends Biochem Sci，2011，36（2）：97-107.
[4]	Cao H，Ren HH，Lin FY，et al. Research status of sphingosine kinase 1［J］. Chin J Clin Pharmacol，2019，35（15）：1706-1708.
[5]	Pchejetski D，Bohler T，Stebbing J，et al. Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer［J］. Nat Rev Urol，2011，8（10）：569-678.
[6]	Jin J，Wang XJ，Zhou WQ，et al. Pharmacological activity of a novel selective S1P1 agonist（prodrug）Syl978［J］. J China Pharm Univ （中国药科大学学报），2014，45 （3）：358-361.
[7]	Benakanakere MR，Zhao J，Galicia JC，et al. Sphingosine kinase-1 is required for toll mediated beta-defensin 2 induction in human oral keratinocytes［J］. PLoS One，2010，5（7）：e11512.
[8]	Zhao Z，Ma J，Hu B，et al. SPHK1 promotes metastasis of thyroid carcinoma through activation of the S1P/S1PR3/Notch signaling pathway［J］. Exp Ther Med，2018，15（6）：5007-5016.
[9]	Argraves KM，Wilkerson BA，Argraves WS，et al. Sphingosine-1-phosphate signaling promotes critical migratory events in vasculogenesis［J］. J Biol Chem，2004，279（48）：50580-50590.
[10]	Olivera A，Kohama T，Edsall L，et al. Sphingosine kinase expression increases intracellular sphingosine-1-phosphate and promotes cell growth and survival［J］. J Cell Biol，1999，147（3）：545-558.
[11]	Xia P，Gamble JR，Wang L，et al. An oncogenic role of sphingosine kinase［J］. Curr Biol，2000，10（23）：1527-1530.
[12]	Lee OH，Kim YM，Lee YM，et al. Sphingosine 1-phosphate induces angiogenesis： its angiogenic action and signaling mechanism in human umbilical vein endothelial cells［J］. Biochem Biophys Res Commun，1999，264（3）：743-750.
[13]	Nava VE，Hobson JP，Murthy S，et al. Sphingosine kinase type 1 promotes estrogen-dependent tumorigenesis of breast cancer MCF-7 cells［J］. Exp Cell Res，2002，281（1）：115-127.
[14]	Min J，Stegner AL，Alexander H，et al. Overexpression of sphingosine-1-phosphate lyase or inhibition of sphingosine kinase in dictyostelium discoideum results in a selective increase in sensitivity to platinum-based chemotherapy drugs［J］. Eukaryot Cell，2004，3（3）：795-805.
[15]	Sauer L，Nunes J，Salunkhe V，et al. Sphingosine kinase 1 inhibition sensitizes hormone-resistant prostate cancer to docetaxel［J］. Int J Cancer，2009，125（11）：2728-2736.
[16]	Bonhoure E，Lauret A，Barnes DJ，et al. Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells［J］. Leukemia，2008，22（5）：971-979.
[17]	Nava VE，Cuvillier O，Edsall LC，et al. Sphingosine enhances apoptosis of radiation-resistant prostate cancer cells［J］. Cancer Res，2000，60（16）：4468-4474.
[18]	Dai SD，Satoru I，Yuki Y，et al. Sphingosine kinase 1 is upregulated with lysophosphatidic acid receptor 2 in human colorectal cancer［J］. World J Gastroenterol，2016，22（8）：2503-2511.
[19]	Cao M，Ji C，Zhou Y，et al. Sphingosine kinase inhibitors： a patent review［J］. Int J Mol Med，2018，41（5）：2450-2460.
[20]	Coward J，Ambrosini G，Musi E，et al. Safingol（L-threo-sphinganine） induces autophagy in solid tumor cells through inhibition of PKC and the PI3-kinase pathway［J］. Autophagy，2009，5（2）：184-193.
[21]	Igarashi Y，Hakomori S. Enzymatic synthesis of N，N-dimethyl-sphingosine： demonstration of the sphingosine：N-methyltransferase in mouse brain［J］. Biochem Biophys Res Commun，1989，164（3）：1411-1416.
[22]	De Jonghe S，Van Overmeire I，Poulton S，et al. Structure-activity relationship of short-chain sphingoid bases as inhibitors of sphingosine kinase［J］. Bioorg Med Chem Lett，1999，9（21）：3175-3180.
[23]	Xiang Y，Asmussen G，Booker M，et al. Discovery of novel sphingosine kinase 1 inhibitors［J］. Bioorg Med Chem Lett，2009，19（21）：6119-6121.
[24]	Xiang Y，Hirth B，Kane JL，et al. Discovery of novel sphingosine kinase-1 inhibitors：part 2［J］. Bioorg Med Chem Lett，2010，20（15）：4550-4554.
[25]	Baek D J，MacRitchie N，Pyne NJ，et al. Synthesis of selective inhibitors of sphingosine kinase 1［J］. Chem Commun，2013，49（21）：2136-2138.
[26]	Schnute ME，McReynolds MD，Kasten T，et al. Modulation of cellular S1P levels with a novel potent and specific inhibitor of sphingosine kinase-1［J］. Biochem J，2012，444（1）：79-88.
[27]	Papakyriakou A，Cencetti F，Puliti E，et al. Glycans meet sphingolipids： structure-based design of glycan containing analogues of a sphingosine kinase inhibitor［J］. ACS Med Chem Lett，2020，11（5）：913-920.
[28]	Zhang Y，Berka V，Song A，et al. Elevated sphingosine-1-phosphate promotes sickling and sickle cell disease progression［J］. J Clin Invest，2014，124（6）：2750-2761.
[29]	Foss FW，T.PMathews，Kharel Y，et al. Synthesis and biological evaluation of sphingosine kinase substrates as sphingosine-1-phosphate receptor prodrugs［J］. Bioorg Med Chem，2009，17（16）：6123-6136.
[30]	Raje MR，Knott K，Kharel Y，et al. Design，synthesis and biological activity of sphingosine kinase 2 selective inhibitors［J］. Bioorg Med Chem，2012，20（1）：183-194.
[31]	Patwardhan NN，Morris EA，Kharel Y，et al. Structure-activity relationship studies and in vivo activity of guanidine-based sphingosine kinase inhibitors： discovery of SphK1- and SphK2-selective inhibitors［J］. J Med Chem，2015，58（4）：1879-1899.
[32]	Congdon MD，Kharel Y，Brown AM，et al. Structure-activity relationship studies and molecular modeling of naphthalene-based sphingosine kinase 2 inhibitors［J］. ACS Med Chem Lett，2016，7（3）：229-234.
[33]	Sibley CD，Morris EA，Kharel Y，et al. Discovery of a small side cavity in sphingosine kinase 2 that enhances inhibitor potency and selectivity［J］. J Med Chem，2020，63（3）：1178-1198.
[34]	French KJ，Schrecengost RS，Lee BD，et al. Discovery and evaluation of inhibitors of human sphingosine kinase［J］. Cancer Res，2003，63（18）：5962-5969.
[35]	French KJ，Upson J J，Keller SN，et al. Antitumor activity of sphingosine kinase inhibitors［J］. J Pharmacol Exp Ther，2006，318（2）：596-603.
[36]	Loveridge C，Tonelli F，Leclercq T. The sphingosine kinase 1 inhibitor 2-（p-hydroxyanilino）-4-（p-chlorophenyl）thiazole induces proteasomal degradation of sphingosine kinase 1 in mammalian cells［J］. J Bio Chem，2010，285（50）：38841-38852.
[37]	Aurelio L，Scullino CV，Pitman MR，et al. From sphingosine kinase to dihydroceramide desaturase：a structure-activity relationship（SAR）study of the enzyme inhibitory and anticancer activity of 4-（（4-（4-chlorophenyl）thiazol-2-yl）amino）phenol（SKI-II）［J］. J Med Chem，2016，59（3）：965-984.
[38]	Gustin DJ，Li Y，Brown ML，et al. Structure guided design of a series of sphingosine kinase（SphK）inhibitors［J］. Bioorg Med Chem Lett，2013，23（16）：4608-4616.
[39]	French KJ，Yan Z，Maines LW，et al. Pharmacology and antitumor activity of ABC294640 a selective inhibitor of sphingosine kinase-2［J］. J Pharm Exp Ther，2010，333（1）：129-139.
[40]	Beljanski V，Knaak C，Yan Z，et al. Combined anticancer effects of sphingosine kinase inhibitors and sorafenib［J］. Invest New Drugs，2011，29（6）：1132-1142.
[41]	Gao P，Y.KPeterson，Smith RA，et al. Characterization of isoenzyme-selective inhibitors of human sphingosine kinases［J］. PLoS One，2012，7（9）：e44543.
[42]	Pitman MR，Powell JA，Coolen C，et al. A selective ATP-competitive sphingosine kinase inhibitor demonstrates anti-cancer properties［J］. Oncotarget，2015，6（9）：7065-7083.
[43]	Kono K，Tanaka M，Ogita T，et al. F-12509A：a new sphingosine kinase inhibitor produced by a discomycete［J］. J Antibiot （Tokyo），2000，53（5）：459-466.
[44]	Bonhoure E，Pchejetski D，Aouali N，et al. Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1［J］. Leukemia，2006，20（1）：95-102.
[45]	Kono K，Sugiura M，Kohama T. Inhibition of recombinant sphingosine kinases by novel inhibitors of microbial origin F-12509A and B-5354c［J］. J Antibiot（Tokyo），2002，55（1）：99-103.
[46]	Kono K，Tanaka M，Ono Y，et al. S-15183a and b new sphingosine kinase inhibitors produced by a fungus［J］. J Antibiot （Tokyo），2001，54（5）：415-420.
[47]	Yoshimitsu Y，Miyagaki J，Oishi S，et al. Synthesis of pachastrissamine（jaspine B）and its derivatives by the late-stage introduction of the C-2 alkyl side-chains using olefin cross metathesis［J］. Tetrahedron，2013，69（21）：4211-4220.

施引文献

资源附件(0)

计量

文章访问数: 265
HTML全文浏览量: 13
PDF下载量: 825
被引次数: 0

鞘氨醇激酶1抑制剂的研究进展

计量

出版历程

Research progress of sphingosine kinase 1 inhibitors

计量

出版历程

目录